Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • McIntosh, C.H.
    Dipeptidyl peptidase IV inhibitors and diabetes therapy (2008), Front. Biosci., 13, 1753-1773.
    View publication on PubMed
Search for more literature for 3.4.14.5

Application

Application Comment Organism
medicine the review focuses mainly on the preclinical studies underlying the development DPP IV inhibitors appropriate for diabetes therapy and their proposed mode of action, and summarized the clinical experience to date Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
ABT-279
-
 Homo sapiens
ABT-341
-
 Homo sapiens
alogliptin
-
 Homo sapiens
ALS 2-0426
-
 Homo sapiens
BI 1356
-
 Homo sapiens
denagliptin
-
 Homo sapiens
GRC8200
-
 Homo sapiens
NVP DPP728
-
 Homo sapiens
P32/98
-
 Homo sapiens
PHX 1149
-
 Homo sapiens
PSN-9301
-
 Homo sapiens
R1438
-
 Homo sapiens
saxagliptin
-
 Homo sapiens
sitagliptin
-
 Homo sapiens
SSR-162369
-
 Homo sapiens
TA-6666
-
 Homo sapiens
TS-021
-
 Homo sapiens
vildagliptin
-
 Homo sapiens

Localization

Localization Comment Organism GeneOntology No. Textmining
membrane integral membrane protein Homo sapiens 16020
-

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
additional information Homo sapiens dipeptidyl peptidase IV is the major enzyme responsible for degrading the incretins in vivo ?
-
 ?

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Posttranslational Modification

Posttranslational Modification Comment Organism
glycoprotein
-
 Homo sapiens

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
additional information dipeptidyl peptidase IV is the major enzyme responsible for degrading the incretins in vivo Homo sapiens ?
-
 ?